Fresenius Kabi strengthens its business with intravenously administered generic drugs (I.V. generics) and expands into oncology drugs with the acquisition of the Indian company Dabur Pharma.
Fresenius Kabi enters into the North American pharmaceuticals market and becomes a globally leading company in the field of I.V. generics via the acquisition of the U.S. based APP Pharmaceuticals.